Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?

The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, preve...

Full description

Saved in:
Bibliographic Details
Published inEBioMedicine Vol. 79; p. 103993
Main Authors Dockrell, Hazel M., McShane, Helen
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.05.2022
Elsevier
Subjects
Advanced Basic Science
Internal Medicine
Personal View
SARS-CoV-2
Tuberculosis
Vaccines
SARS-CoV-2
Tuberculosis
Vaccines
Online AccessGet full text
ISSN2352-3964
2352-3964
DOI10.1016/j.ebiom.2022.103993

Cover

Abstract The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines.
AbstractList The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines.
SummaryThe Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines.
The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines.The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed tuberculosis vaccines, although there much active research and a vaccine development pipeline, with vaccines designed to prevent infection, prevent disease, or accelerate TB treatment. These vaccines are of different types, and designed to replace BCG, or to boost immunity following BCG vaccination. This viewpoint discusses why, when it has been possible to develop new vaccines for SARS-CoV-2 so quickly, it is taking so long to develop new tuberculosis vaccines.
ArticleNumber 103993
Author Dockrell, Hazel M.
McShane, Helen
Author_xml – sequence: 1
  givenname: Hazel M.
  surname: Dockrell
  fullname: Dockrell, Hazel M.
  email: hazel.dockrell@lshtm.ac.uk
  organization: Department of Infection Biology, London School of Hygiene & Tropical Medicine, Keppel Street, London WCE 7HT, UK
– sequence: 2
  givenname: Helen
  surname: McShane
  fullname: McShane, Helen
  organization: The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7DQ, UK
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35427852$$D View this record in MEDLINE/PubMed
BookMark eNqFks1u1DAUhSNUREvpEyAhL9nM4N8kFqIIjfipqMSCsr5ynJsZTzN2sZNB3fEOvCFPgtNpUVsJusrVzTnflXzO02LPB49F8ZzROaOsfLWeY-PCZs4p53kjtBaPigMuFJ8JXcq9W_N-cZTSmlLKlMzL-kmxL_JU1YofFJ_PxgajHfuQXCJbY63zmIjzZFghwWhI6MgibF07Y5r8_vmL_FiZgWTtYM6dX5IxkRRIH_zy7bPicWf6hEfX38Pi24f3Z4tPs9MvH08W705nthR8mAmlaMd4SWnF86RtU2vN2lahobXmFUputKykUJQjayuFiA03wqrKlFTU4rA42XHbYNZwEd3GxEsIxsHVIsQlmDg42yNIRktpSqulVFJTZqq2UQ3nXUO7uhYys453rIux2WBr0Q_R9Hegd_94t4Jl2IKmlFOpMuDlNSCG7yOmATYuWex74zGMCXipWKmp1CxLX9y-9ffITRpZoHcCG0NKETuwbjCDC9Np1wOjMIUPa7gKH6bwYRd-9op73hv8_11vdi7MeW0dRkjWobfYuoh2yA_qHvAf3_Pb3nlnTX-Ol5jWYYw-VwEYJA4Uvk6lnDrJea5jVU2A1_8GPHj-D6cW73A
CitedBy_id crossref_primary_10_1016_S0140_6736_23_01379_X
crossref_primary_10_12688_wellcomeopenres_18767_2
crossref_primary_10_1097_MS9_0000000000002446
crossref_primary_10_1038_s41541_023_00750_7
crossref_primary_10_1136_jme_2023_109234
crossref_primary_10_3346_jkms_2023_38_e43
crossref_primary_10_1038_s41467_024_52846_w
crossref_primary_10_12688_wellcomeopenres_19811_2
crossref_primary_10_3390_pharmaceutics15010194
crossref_primary_10_1016_j_nano_2023_102653
crossref_primary_10_12688_wellcomeopenres_18767_1
crossref_primary_10_12688_wellcomeopenres_19811_1
crossref_primary_10_3390_biom13060968
crossref_primary_10_1016_S2214_109X_23_00123_7
crossref_primary_10_1128_mbio_00220_23
crossref_primary_10_1007_s42250_022_00423_3
crossref_primary_10_3390_vaccines12050477
crossref_primary_10_1016_j_tips_2022_08_007
crossref_primary_10_3389_ftubr_2024_1487518
Cites_doi 10.1164/rccm.201908-1580OC
10.1016/j.vaccine.2012.12.053
10.1038/s41577-018-0025-3
10.1016/j.ijid.2017.01.030
10.1038/s41590-020-0782-6
10.1016/j.ijid.2016.10.018
10.1007/s00281-020-00794-0
10.3389/fimmu.2017.01147
10.1056/NEJMc2001468
10.1093/cid/cit790
10.1038/ng.590
10.3390/app11199250
10.1164/rccm.201003-0334OC
10.1016/j.tube.2013.12.006
10.1016/S0140-6736(06)68507-3
10.1016/S2213-2600(15)00435-X
10.1016/j.chom.2018.06.004
10.1098/rstb.2013.0437
10.1016/j.ijid.2020.01.042
10.1016/j.cell.2016.08.072
10.1128/IAI.72.11.6324-6329.2004
10.1164/rccm.201912-2408ED
10.1073/pnas.0700869104
10.1016/S0140-6736(02)08353-8
10.1128/MMBR.00021-14
10.1056/NEJMoa1714021
10.4161/hv.8570
10.1016/S1473-3099(21)00403-5
10.1016/j.chom.2020.02.001
10.1016/j.tube.2016.09.004
10.1038/nrmicro2236
10.1371/journal.pone.0005264
10.1038/s41591-018-0319-9
10.3389/fimmu.2021.640916
10.1038/31159
10.1056/NEJMoa011110
10.3389/fmicb.2021.750124
10.1097/COH.0b013e3283339309
10.1016/S1473-3099(19)30625-5
10.1038/ncomms11290
10.1172/JCI24617
10.1128/microbiolspec.TBTB2-0029-2016
10.1172/jci.insight.130090
10.1056/NEJMoa1909953
10.1016/j.vaccine.2021.06.049
10.1016/S2214-109X(20)30288-6
10.1128/CMR.00021-18
10.1080/14760584.2019.1692657
10.1038/nm.4473
10.1038/s41586-020-03041-6
10.1038/s41586-019-1817-8
10.1038/ncomms3836
10.1016/j.chom.2020.10.003
ContentType Journal Article
Copyright 2022 The Authors
The Authors
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
2022 The Authors 2022
Copyright_xml – notice: 2022 The Authors
– notice: The Authors
– notice: Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
– notice: 2022 The Authors 2022
DBID 6I.
AAFTH
AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.1016/j.ebiom.2022.103993
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
PubMed


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2352-3964
EndPage 103993
ExternalDocumentID oai_doaj_org_article_41064a6c94454901a7db5b22fb0f8834
PMC9002045
35427852
10_1016_j_ebiom_2022_103993
S2352396422001773
1_s2_0_S2352396422001773
Genre Journal Article
Review
GroupedDBID .1-
.FO
0R~
4.4
457
53G
5VS
AAEDT
AAEDW
AAIKJ
AALRI
AAMRU
AAXUO
AAYWO
ABMAC
ACGFS
ACVFH
ADBBV
ADCNI
ADEZE
ADRAZ
ADVLN
AEUPX
AEXQZ
AFPUW
AFRHN
AFTJW
AGHFR
AIGII
AITUG
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AOIJS
APXCP
BCNDV
EBS
EJD
FDB
GROUPED_DOAJ
HYE
HZ~
IPNFZ
KQ8
M41
M48
O9-
OK1
RIG
ROL
RPM
SSZ
Z5R
0SF
6I.
AACTN
AAFTH
AFCTW
NCXOZ
AAYXX
CITATION
NPM
7X8
5PM
ID FETCH-LOGICAL-c632t-3550f126007250f9cb8991dd5ea08927e42a94743502e1d75eeeb2a3c57a60383
IEDL.DBID M48
ISSN 2352-3964
IngestDate Wed Aug 27 00:56:23 EDT 2025
Tue Sep 30 16:42:37 EDT 2025
Fri Sep 05 14:20:16 EDT 2025
Thu Apr 03 07:06:53 EDT 2025
Wed Oct 01 01:06:10 EDT 2025
Thu Apr 24 23:04:59 EDT 2025
Sun Apr 06 06:52:58 EDT 2025
Tue Feb 25 20:01:53 EST 2025
Tue Aug 26 16:33:51 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords SARS-CoV-2
Tuberculosis
Vaccines
Language English
License This is an open access article under the CC BY-NC-ND license.
Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c632t-3550f126007250f9cb8991dd5ea08927e42a94743502e1d75eeeb2a3c57a60383
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1016/j.ebiom.2022.103993
PMID 35427852
PQID 2651690491
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_41064a6c94454901a7db5b22fb0f8834
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9002045
proquest_miscellaneous_2651690491
pubmed_primary_35427852
crossref_citationtrail_10_1016_j_ebiom_2022_103993
crossref_primary_10_1016_j_ebiom_2022_103993
elsevier_sciencedirect_doi_10_1016_j_ebiom_2022_103993
elsevier_clinicalkeyesjournals_1_s2_0_S2352396422001773
elsevier_clinicalkey_doi_10_1016_j_ebiom_2022_103993
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-05-01
PublicationDateYYYYMMDD 2022-05-01
PublicationDate_xml – month: 05
  year: 2022
  text: 2022-05-01
  day: 01
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle EBioMedicine
PublicationTitleAlternate EBioMedicine
PublicationYear 2022
Publisher Elsevier B.V
Elsevier
Publisher_xml – name: Elsevier B.V
– name: Elsevier
References Mangtani, Abubakar, Ariti (bib0005) 2014; 58
Hansen, Zak, Xu (bib0055) 2018; 24
Cohen, Meintjes (bib0020) 2010; 5
WHO Global TB Report 2021.
Brazier, McShane (bib0008) 2020; 42
Poyntz, Stylianou, Griffiths, Marsay, Checkley, McShane (bib0022) 2014; 94
Rothe, Schunk, Sothmann (bib0031) 2020; 382
McShane (bib0034) 2020; 201
Accessed 20 January 2022.
TB vaccine pipeline, 2021.
Von Eschen, Morrison, Braun (bib0043) 2009; 5
Nieuwenhuizen, Kulkarni, Shaligram (bib0010) 2017; 8
Ernst (bib0032) 2018; 24
Cardona, Williams (bib0018) 2017; 56
Cole, Brosch, Parkhill (bib0024) 1998; 393
clinicaltrials.gov NCT03512249
Simmons, Stein, Seshadri (bib0030) 2018; 18
Ewer, O'Hara, Duncan (bib0033) 2013; 4
Müller, Tanner, Matsumiya (bib0021) 2019; 4
Lange, Aaby, Behr (bib0001) 2022; 22
Tuberculosis Research Funding Trends 2005-2019. Stop TB Partnership and Treatment Action Group.
Accessed 5 April 2022.
Saramago, Magalhães, Pinheiro (bib0009) 2021; 11
Xue, Stavropoulos, Yang (bib0045) 2004; 72
Clinicaltrials.gov NCT04975178
Grode, Seiler, Baumann (bib0049) 2005; 115
Basaraba, Hunter (bib0016) 2017; 5
Resolution from United Nations General Assembly high-level meeting on tuberculosis, 26 September 2018, Resolution document A/RES/73/3 accessed 28 February 2022.
Accessed 7 March 2022.
Peng, Mentzer, Liu (bib0038) 2020; 21
Kaufmann (bib0002) 2021; 12
Hawn, Day, Scriba (bib0046) 2014; 78
Collaboration for TB Vaccine Discovery.
Darrah, Zeppa, Maiello (bib0059) 2020; 577
Fletcher, Snowden, Landry (bib0039) 2016; 7
Verreck, Vervenne, Kondova (bib0052) 2009; 4
Kaufmann, Weiner, von Reyn (bib0012) 2017; 56
Brosch, Gordon, Garnier (bib0003) 2007; 104
Plumlee, Duffy, Gern (bib0017) 2021; 29
Trunz, Fine, Dye (bib0004) 2006; 367
Martín, Marinova, Aguiló, Gonzalo-Asensio (bib0011) 2021; 39
Clinicaltrials.gov NCT04865237; NCT04864548
Davids, Pooran, Hermann (bib0035) 2020; 201
Accessed 23 January 2022.
Morrison, McShane (bib0042) 2021; 12
Wu, Peng, Huang (bib0023) 2020; 27
Kagina, Abel, Scriba (bib0040) 2010; 182
Nemes, Geldenhuys, Rozot (bib0047) 2018; 379
Comas, Chakravartti, Small (bib0025) 2010; 42
Drain, Bajema, Dowdy (bib0029) 2018; 31
Esmail, Barry, Young, Wilkinson (bib0027) 2014; 369
Stylianou, Paul, Reljic, McShane (bib0056) 2019; 18
Migliori, Tiberi, Zumla (bib0013) 2020; 92S
Lu, Chung, Rosebrock (bib0041) 2016; 167
Keane, Gershon, Wise (bib0028) 2001; 345
Dijkman, Sombroek, Vervenne (bib0057) 2019; 25
Sharpe, White, Sarfas (bib0058) 2016; 101
TB Vaccine Development Pathway.
Spertini, Audran, Chakour (bib0053) 2015; 3
TuBerculosis Vaccine Initiative.
Hogan, Jewell, Sherrard-Smith (bib0015) 2020; 8
Barry, Boshoff, Dartois (bib0026) 2009; 7
Clinicaltrials.gov NCT04351685
McMahan, Yu, Mercado (bib0037) 2021; 590
Schrager, Vekemens, Drager, Lewinsohn, Olesen (bib0007) 2020; 20
Black, Weir, Floyd (bib0019) 2002; 359
Tait, Hatherill, Van Der Meeren (bib0044) 2019; 381
Grode, Ganoza, Brohm, Weiner, Eisele, Kaufmann (bib0050) 2013; 31
Esmail (10.1016/j.ebiom.2022.103993_bib0027) 2014; 369
Migliori (10.1016/j.ebiom.2022.103993_bib0013) 2020; 92S
Lu (10.1016/j.ebiom.2022.103993_bib0041) 2016; 167
Martín (10.1016/j.ebiom.2022.103993_bib0011) 2021; 39
McMahan (10.1016/j.ebiom.2022.103993_bib0037) 2021; 590
Poyntz (10.1016/j.ebiom.2022.103993_bib0022) 2014; 94
Von Eschen (10.1016/j.ebiom.2022.103993_bib0043) 2009; 5
Cole (10.1016/j.ebiom.2022.103993_bib0024) 1998; 393
Simmons (10.1016/j.ebiom.2022.103993_bib0030) 2018; 18
10.1016/j.ebiom.2022.103993_bib0048
Saramago (10.1016/j.ebiom.2022.103993_bib0009) 2021; 11
Lange (10.1016/j.ebiom.2022.103993_bib0001) 2022; 22
10.1016/j.ebiom.2022.103993_bib0006
Nieuwenhuizen (10.1016/j.ebiom.2022.103993_bib0010) 2017; 8
Spertini (10.1016/j.ebiom.2022.103993_bib0053) 2015; 3
Schrager (10.1016/j.ebiom.2022.103993_bib0007) 2020; 20
Nemes (10.1016/j.ebiom.2022.103993_bib0047) 2018; 379
Hansen (10.1016/j.ebiom.2022.103993_bib0055) 2018; 24
Cardona (10.1016/j.ebiom.2022.103993_bib0018) 2017; 56
Xue (10.1016/j.ebiom.2022.103993_bib0045) 2004; 72
Brazier (10.1016/j.ebiom.2022.103993_bib0008) 2020; 42
Verreck (10.1016/j.ebiom.2022.103993_bib0052) 2009; 4
10.1016/j.ebiom.2022.103993_bib0051
Hawn (10.1016/j.ebiom.2022.103993_bib0046) 2014; 78
Tait (10.1016/j.ebiom.2022.103993_bib0044) 2019; 381
Müller (10.1016/j.ebiom.2022.103993_bib0021) 2019; 4
10.1016/j.ebiom.2022.103993_bib0054
Hogan (10.1016/j.ebiom.2022.103993_bib0015) 2020; 8
McShane (10.1016/j.ebiom.2022.103993_bib0034) 2020; 201
10.1016/j.ebiom.2022.103993_bib0014
Black (10.1016/j.ebiom.2022.103993_bib0019) 2002; 359
Fletcher (10.1016/j.ebiom.2022.103993_bib0039) 2016; 7
Ernst (10.1016/j.ebiom.2022.103993_bib0032) 2018; 24
Plumlee (10.1016/j.ebiom.2022.103993_bib0017) 2021; 29
Davids (10.1016/j.ebiom.2022.103993_bib0035) 2020; 201
Morrison (10.1016/j.ebiom.2022.103993_bib0042) 2021; 12
Keane (10.1016/j.ebiom.2022.103993_bib0028) 2001; 345
Ewer (10.1016/j.ebiom.2022.103993_bib0033) 2013; 4
Grode (10.1016/j.ebiom.2022.103993_bib0049) 2005; 115
Basaraba (10.1016/j.ebiom.2022.103993_bib0016) 2017; 5
10.1016/j.ebiom.2022.103993_bib0060
10.1016/j.ebiom.2022.103993_bib0062
Kaufmann (10.1016/j.ebiom.2022.103993_bib0002) 2021; 12
Stylianou (10.1016/j.ebiom.2022.103993_bib0056) 2019; 18
10.1016/j.ebiom.2022.103993_bib0061
10.1016/j.ebiom.2022.103993_bib0064
Comas (10.1016/j.ebiom.2022.103993_bib0025) 2010; 42
10.1016/j.ebiom.2022.103993_bib0063
Mangtani (10.1016/j.ebiom.2022.103993_bib0005) 2014; 58
Darrah (10.1016/j.ebiom.2022.103993_bib0059) 2020; 577
Dijkman (10.1016/j.ebiom.2022.103993_bib0057) 2019; 25
Kaufmann (10.1016/j.ebiom.2022.103993_bib0012) 2017; 56
Peng (10.1016/j.ebiom.2022.103993_bib0038) 2020; 21
Trunz (10.1016/j.ebiom.2022.103993_bib0004) 2006; 367
Kagina (10.1016/j.ebiom.2022.103993_bib0040) 2010; 182
Wu (10.1016/j.ebiom.2022.103993_bib0023) 2020; 27
Rothe (10.1016/j.ebiom.2022.103993_bib0031) 2020; 382
Cohen (10.1016/j.ebiom.2022.103993_bib0020) 2010; 5
Grode (10.1016/j.ebiom.2022.103993_bib0050) 2013; 31
Barry (10.1016/j.ebiom.2022.103993_bib0026) 2009; 7
Drain (10.1016/j.ebiom.2022.103993_bib0029) 2018; 31
10.1016/j.ebiom.2022.103993_bib0036
Brosch (10.1016/j.ebiom.2022.103993_bib0003) 2007; 104
Sharpe (10.1016/j.ebiom.2022.103993_bib0058) 2016; 101
References_xml – volume: 104
  start-page: 5596
  year: 2007
  end-page: 5601
  ident: bib0003
  article-title: Genome plasticity of BCG and impact on vaccine efficacy
  publication-title: Proc Natl Acad Sci USA
– reference: Accessed 5 April 2022.
– volume: 4
  start-page: e5264
  year: 2009
  ident: bib0052
  article-title: MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques
  publication-title: PLoS One
– volume: 4
  start-page: e130090
  year: 2019
  ident: bib0021
  article-title: Cytomegalovirus infection is a risk factor for tuberculosis disease in infants
  publication-title: JCI Insight
– volume: 31
  start-page: 1340
  year: 2013
  end-page: 1348
  ident: bib0050
  article-title: Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial
  publication-title: Vaccine
– volume: 24
  start-page: 34
  year: 2018
  end-page: 42
  ident: bib0032
  article-title: Mechanisms of M. tuberculosis immune evasion as challenges to TB vaccine design
  publication-title: Cell Host Microbe
– reference: Accessed 20 January 2022.
– volume: 369
  year: 2014
  ident: bib0027
  article-title: The ongoing challenge of latent tuberculosis
  publication-title: Philos Trans R Soc Lond B Biol Sci
– reference: TuBerculosis Vaccine Initiative.
– volume: 3
  start-page: 953
  year: 2015
  end-page: 962
  ident: bib0053
  article-title: Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial
  publication-title: Lancet Respir Med
– reference: Collaboration for TB Vaccine Discovery.
– volume: 42
  start-page: 498
  year: 2010
  end-page: 503
  ident: bib0025
  article-title: Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved
  publication-title: Nat Genet
– volume: 182
  start-page: 1073
  year: 2010
  end-page: 1079
  ident: bib0040
  article-title: Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns
  publication-title: Am J Respir Crit Care Med
– volume: 18
  start-page: 1271
  year: 2019
  end-page: 1284
  ident: bib0056
  article-title: Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges
  publication-title: Expert Rev Vaccines
– volume: 201
  start-page: 1277
  year: 2020
  end-page: 1291
  ident: bib0035
  article-title: A human lung challenge model to evaluate the safety and immunogenicity of PPD and live bacillus Calmette-Guérin
  publication-title: Am J Respir Crit Care Med
– volume: 590
  start-page: 630
  year: 2021
  end-page: 634
  ident: bib0037
  article-title: Correlates of protection against SARS-CoV-2 in rhesus macaques
  publication-title: Nature
– volume: 5
  start-page: 475
  year: 2009
  end-page: 482
  ident: bib0043
  article-title: The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans
  publication-title: Hum Vaccin
– volume: 42
  start-page: 315
  year: 2020
  end-page: 331
  ident: bib0008
  article-title: Towards new TB vaccines
  publication-title: Semin Immunopathol
– volume: 393
  start-page: 537
  year: 1998
  end-page: 544
  ident: bib0024
  article-title: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
  publication-title: Nature
– volume: 58
  start-page: 470
  year: 2014
  end-page: 480
  ident: bib0005
  article-title: Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials
  publication-title: Clin Infect Dis
– reference: Tuberculosis Research Funding Trends 2005-2019. Stop TB Partnership and Treatment Action Group.
– volume: 94
  start-page: 226
  year: 2014
  end-page: 237
  ident: bib0022
  article-title: Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis
  publication-title: Tuberculosis (Edinb)
– volume: 31
  start-page: e00021
  year: 2018
  ident: bib0029
  article-title: Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection
  publication-title: Clin Microbiol Rev
– volume: 201
  start-page: 1180
  year: 2020
  end-page: 1181
  ident: bib0034
  article-title: Controlled human infection models: is it really feasible to give people tuberculosis?
  publication-title: Am J Respir Crit Care Med
– volume: 5
  year: 2017
  ident: bib0016
  article-title: Pathology of tuberculosis: how the pathology of human tuberculosis informs and directs animal models
  publication-title: Microbiol Spectr
– volume: 4
  start-page: 2836
  year: 2013
  ident: bib0033
  article-title: Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
  publication-title: Nat Commun
– volume: 359
  start-page: 1393
  year: 2002
  end-page: 1401
  ident: bib0019
  article-title: BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies
  publication-title: Lancet
– volume: 367
  start-page: 1173
  year: 2006
  end-page: 1180
  ident: bib0004
  article-title: Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness
  publication-title: Lancet
– reference: TB vaccine pipeline, 2021.
– reference: . Accessed 7 March 2022.
– volume: 56
  start-page: 263
  year: 2017
  end-page: 267
  ident: bib0012
  article-title: Novel approaches to tuberculosis vaccine development
  publication-title: Int J Infect Dis
– volume: 7
  start-page: 845
  year: 2009
  end-page: 855
  ident: bib0026
  article-title: The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
  publication-title: Nat Rev Microbiol
– reference: Clinicaltrials.gov NCT04975178
– volume: 345
  start-page: 1098
  year: 2001
  end-page: 1104
  ident: bib0028
  article-title: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
  publication-title: N Engl J Med
– reference: Accessed 23 January 2022.
– volume: 25
  start-page: 255
  year: 2019
  end-page: 262
  ident: bib0057
  article-title: Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques
  publication-title: Nat Med
– volume: 577
  start-page: 95
  year: 2020
  end-page: 102
  ident: bib0059
  article-title: Prevention of tuberculosis in macaques after intravenous BCG immunization
  publication-title: Nature
– volume: 381
  start-page: 2429
  year: 2019
  end-page: 2439
  ident: bib0044
  article-title: Final analysis of a trial of M72/AS01
  publication-title: N Engl J Med
– volume: 382
  start-page: 970
  year: 2020
  end-page: 971
  ident: bib0031
  article-title: Transmission of 2019-nCoV infection from an asymptomatic contact in Germany
  publication-title: N Engl J Med
– volume: 8
  start-page: 1147
  year: 2017
  ident: bib0010
  article-title: The recombinant bacille Calmette-Guérin vaccine VPM1002: ready for clinical efficacy testing
  publication-title: Front Immunol
– reference: clinicaltrials.gov NCT03512249
– volume: 20
  start-page: e28
  year: 2020
  end-page: e37
  ident: bib0007
  article-title: The status of tuberculosis vaccine development
  publication-title: Lancet Infect Dis
– volume: 27
  start-page: 325
  year: 2020
  end-page: 328
  ident: bib0023
  article-title: Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China
  publication-title: Cell Host Microbe
– volume: 18
  start-page: 575
  year: 2018
  end-page: 589
  ident: bib0030
  article-title: Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection
  publication-title: Nat Rev Immunol
– reference: TB Vaccine Development Pathway.
– volume: 72
  start-page: 6324
  year: 2004
  end-page: 6329
  ident: bib0045
  article-title: RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection
  publication-title: Infect Immun
– volume: 24
  start-page: 130
  year: 2018
  end-page: 143
  ident: bib0055
  article-title: Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine
  publication-title: Nat Med
– reference: Clinicaltrials.gov NCT04351685
– volume: 12
  year: 2021
  ident: bib0042
  article-title: Local pulmonary immunological biomarkers in tuberculosis
  publication-title: Front Immunol
– reference: Clinicaltrials.gov NCT04865237; NCT04864548
– volume: 379
  start-page: 138
  year: 2018
  end-page: 149
  ident: bib0047
  article-title: Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination
  publication-title: N Engl J Med
– volume: 92S
  start-page: S15
  year: 2020
  end-page: S25
  ident: bib0013
  article-title: MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network
  publication-title: Int J Infect Dis
– volume: 22
  start-page: e2
  year: 2022
  end-page: e12
  ident: bib0001
  article-title: 100 years of Mycobacterium bovis bacille Calmette-Guérin
  publication-title: Lancet Infect Dis
– volume: 8
  start-page: e1132
  year: 2020
  end-page: e1141
  ident: bib0015
  article-title: Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study
  publication-title: Lancet Glob Health
– volume: 29
  start-page: 68
  year: 2021
  end-page: 82
  ident: bib0017
  article-title: Ultra-low dose aerosol infection of mice with mycobacterium tuberculosis more closely models human tuberculosis
  publication-title: Cell Host Microbe
– volume: 5
  start-page: 61
  year: 2010
  end-page: 69
  ident: bib0020
  article-title: Management of individuals requiring antiretroviral therapy and TB treatment
  publication-title: Curr Opin HIV AIDS
– volume: 167
  start-page: 433
  year: 2016
  end-page: 443
  ident: bib0041
  article-title: A Functional Role for Antibodies in Tuberculosis
  publication-title: Cell
– reference: WHO Global TB Report 2021.
– volume: 56
  start-page: 268
  year: 2017
  end-page: 273
  ident: bib0018
  article-title: Experimental animal modelling for TB vaccine development
  publication-title: Int J Infect Dis
– volume: 7
  start-page: 11290
  year: 2016
  ident: bib0039
  article-title: T-cell activation is an immune correlate of risk in BCG vaccinated infants
  publication-title: Nat Commun
– volume: 12
  year: 2021
  ident: bib0002
  article-title: Vaccine development against tuberculosis over the last 140 years: failure as part of success
  publication-title: Front Microbiol
– reference: Resolution from United Nations General Assembly high-level meeting on tuberculosis, 26 September 2018, Resolution document A/RES/73/3 accessed 28 February 2022.
– volume: 101
  start-page: 174
  year: 2016
  end-page: 190
  ident: bib0058
  article-title: Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations
  publication-title: Tuberculosis (Edinb)
– volume: 78
  start-page: 650
  year: 2014
  end-page: 671
  ident: bib0046
  article-title: Tuberculosis vaccines and prevention of infection
  publication-title: Microbiol Mol Biol Rev
– volume: 21
  start-page: 1336
  year: 2020
  end-page: 1345
  ident: bib0038
  article-title: Broad and strong memory CD4
  publication-title: Nat Immunol
– volume: 115
  start-page: 2472
  year: 2005
  end-page: 2479
  ident: bib0049
  article-title: Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin
  publication-title: J Clin Invest
– volume: 39
  start-page: 7277
  year: 2021
  end-page: 7285
  ident: bib0011
  article-title: MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG
  publication-title: Vaccine
– reference: . Accessed 20 January 2022.
– volume: 11
  start-page: 9250
  year: 2021
  ident: bib0009
  article-title: Tuberculosis vaccines: an update of recent and ongoing clinical trials
  publication-title: Appl Sci
– volume: 201
  start-page: 1277
  year: 2020
  ident: 10.1016/j.ebiom.2022.103993_bib0035
  article-title: A human lung challenge model to evaluate the safety and immunogenicity of PPD and live bacillus Calmette-Guérin
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201908-1580OC
– volume: 31
  start-page: 1340
  year: 2013
  ident: 10.1016/j.ebiom.2022.103993_bib0050
  article-title: Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2012.12.053
– volume: 18
  start-page: 575
  year: 2018
  ident: 10.1016/j.ebiom.2022.103993_bib0030
  article-title: Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-018-0025-3
– ident: 10.1016/j.ebiom.2022.103993_bib0051
– volume: 56
  start-page: 268
  year: 2017
  ident: 10.1016/j.ebiom.2022.103993_bib0018
  article-title: Experimental animal modelling for TB vaccine development
  publication-title: Int J Infect Dis
  doi: 10.1016/j.ijid.2017.01.030
– volume: 21
  start-page: 1336
  year: 2020
  ident: 10.1016/j.ebiom.2022.103993_bib0038
  article-title: Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
  publication-title: Nat Immunol
  doi: 10.1038/s41590-020-0782-6
– volume: 56
  start-page: 263
  year: 2017
  ident: 10.1016/j.ebiom.2022.103993_bib0012
  article-title: Novel approaches to tuberculosis vaccine development
  publication-title: Int J Infect Dis
  doi: 10.1016/j.ijid.2016.10.018
– volume: 42
  start-page: 315
  year: 2020
  ident: 10.1016/j.ebiom.2022.103993_bib0008
  article-title: Towards new TB vaccines
  publication-title: Semin Immunopathol
  doi: 10.1007/s00281-020-00794-0
– volume: 8
  start-page: 1147
  year: 2017
  ident: 10.1016/j.ebiom.2022.103993_bib0010
  article-title: The recombinant bacille Calmette-Guérin vaccine VPM1002: ready for clinical efficacy testing
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2017.01147
– volume: 382
  start-page: 970
  year: 2020
  ident: 10.1016/j.ebiom.2022.103993_bib0031
  article-title: Transmission of 2019-nCoV infection from an asymptomatic contact in Germany
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2001468
– volume: 58
  start-page: 470
  year: 2014
  ident: 10.1016/j.ebiom.2022.103993_bib0005
  article-title: Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/cit790
– volume: 42
  start-page: 498
  year: 2010
  ident: 10.1016/j.ebiom.2022.103993_bib0025
  article-title: Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved
  publication-title: Nat Genet
  doi: 10.1038/ng.590
– volume: 11
  start-page: 9250
  year: 2021
  ident: 10.1016/j.ebiom.2022.103993_bib0009
  article-title: Tuberculosis vaccines: an update of recent and ongoing clinical trials
  publication-title: Appl Sci
  doi: 10.3390/app11199250
– ident: 10.1016/j.ebiom.2022.103993_bib0060
– volume: 182
  start-page: 1073
  year: 2010
  ident: 10.1016/j.ebiom.2022.103993_bib0040
  article-title: Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201003-0334OC
– volume: 94
  start-page: 226
  year: 2014
  ident: 10.1016/j.ebiom.2022.103993_bib0022
  article-title: Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis
  publication-title: Tuberculosis (Edinb)
  doi: 10.1016/j.tube.2013.12.006
– ident: 10.1016/j.ebiom.2022.103993_bib0064
– ident: 10.1016/j.ebiom.2022.103993_bib0036
– volume: 367
  start-page: 1173
  year: 2006
  ident: 10.1016/j.ebiom.2022.103993_bib0004
  article-title: Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness
  publication-title: Lancet
  doi: 10.1016/S0140-6736(06)68507-3
– volume: 3
  start-page: 953
  year: 2015
  ident: 10.1016/j.ebiom.2022.103993_bib0053
  article-title: Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(15)00435-X
– volume: 24
  start-page: 34
  year: 2018
  ident: 10.1016/j.ebiom.2022.103993_bib0032
  article-title: Mechanisms of M. tuberculosis immune evasion as challenges to TB vaccine design
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2018.06.004
– volume: 369
  year: 2014
  ident: 10.1016/j.ebiom.2022.103993_bib0027
  article-title: The ongoing challenge of latent tuberculosis
  publication-title: Philos Trans R Soc Lond B Biol Sci
  doi: 10.1098/rstb.2013.0437
– volume: 92S
  start-page: S15
  year: 2020
  ident: 10.1016/j.ebiom.2022.103993_bib0013
  article-title: MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network
  publication-title: Int J Infect Dis
  doi: 10.1016/j.ijid.2020.01.042
– volume: 167
  start-page: 433
  year: 2016
  ident: 10.1016/j.ebiom.2022.103993_bib0041
  article-title: A Functional Role for Antibodies in Tuberculosis
  publication-title: Cell
  doi: 10.1016/j.cell.2016.08.072
– volume: 72
  start-page: 6324
  issue: 11
  year: 2004
  ident: 10.1016/j.ebiom.2022.103993_bib0045
  article-title: RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection
  publication-title: Infect Immun
  doi: 10.1128/IAI.72.11.6324-6329.2004
– ident: 10.1016/j.ebiom.2022.103993_bib0014
– volume: 201
  start-page: 1180
  year: 2020
  ident: 10.1016/j.ebiom.2022.103993_bib0034
  article-title: Controlled human infection models: is it really feasible to give people tuberculosis?
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201912-2408ED
– ident: 10.1016/j.ebiom.2022.103993_bib0063
– volume: 104
  start-page: 5596
  year: 2007
  ident: 10.1016/j.ebiom.2022.103993_bib0003
  article-title: Genome plasticity of BCG and impact on vaccine efficacy
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.0700869104
– volume: 359
  start-page: 1393
  year: 2002
  ident: 10.1016/j.ebiom.2022.103993_bib0019
  article-title: BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies
  publication-title: Lancet
  doi: 10.1016/S0140-6736(02)08353-8
– volume: 78
  start-page: 650
  year: 2014
  ident: 10.1016/j.ebiom.2022.103993_bib0046
  article-title: Tuberculosis vaccines and prevention of infection
  publication-title: Microbiol Mol Biol Rev
  doi: 10.1128/MMBR.00021-14
– volume: 379
  start-page: 138
  year: 2018
  ident: 10.1016/j.ebiom.2022.103993_bib0047
  article-title: Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1714021
– volume: 5
  start-page: 475
  year: 2009
  ident: 10.1016/j.ebiom.2022.103993_bib0043
  article-title: The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans
  publication-title: Hum Vaccin
  doi: 10.4161/hv.8570
– volume: 22
  start-page: e2
  year: 2022
  ident: 10.1016/j.ebiom.2022.103993_bib0001
  article-title: 100 years of Mycobacterium bovis bacille Calmette-Guérin
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(21)00403-5
– volume: 27
  start-page: 325
  year: 2020
  ident: 10.1016/j.ebiom.2022.103993_bib0023
  article-title: Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2020.02.001
– volume: 101
  start-page: 174
  year: 2016
  ident: 10.1016/j.ebiom.2022.103993_bib0058
  article-title: Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations
  publication-title: Tuberculosis (Edinb)
  doi: 10.1016/j.tube.2016.09.004
– volume: 7
  start-page: 845
  year: 2009
  ident: 10.1016/j.ebiom.2022.103993_bib0026
  article-title: The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
  publication-title: Nat Rev Microbiol
  doi: 10.1038/nrmicro2236
– volume: 4
  start-page: e5264
  year: 2009
  ident: 10.1016/j.ebiom.2022.103993_bib0052
  article-title: MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0005264
– volume: 25
  start-page: 255
  year: 2019
  ident: 10.1016/j.ebiom.2022.103993_bib0057
  article-title: Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques
  publication-title: Nat Med
  doi: 10.1038/s41591-018-0319-9
– volume: 12
  year: 2021
  ident: 10.1016/j.ebiom.2022.103993_bib0042
  article-title: Local pulmonary immunological biomarkers in tuberculosis
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.640916
– volume: 393
  start-page: 537
  year: 1998
  ident: 10.1016/j.ebiom.2022.103993_bib0024
  article-title: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
  publication-title: Nature
  doi: 10.1038/31159
– ident: 10.1016/j.ebiom.2022.103993_bib0062
– volume: 345
  start-page: 1098
  year: 2001
  ident: 10.1016/j.ebiom.2022.103993_bib0028
  article-title: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa011110
– volume: 12
  year: 2021
  ident: 10.1016/j.ebiom.2022.103993_bib0002
  article-title: Vaccine development against tuberculosis over the last 140 years: failure as part of success
  publication-title: Front Microbiol
  doi: 10.3389/fmicb.2021.750124
– volume: 5
  start-page: 61
  year: 2010
  ident: 10.1016/j.ebiom.2022.103993_bib0020
  article-title: Management of individuals requiring antiretroviral therapy and TB treatment
  publication-title: Curr Opin HIV AIDS
  doi: 10.1097/COH.0b013e3283339309
– volume: 20
  start-page: e28
  year: 2020
  ident: 10.1016/j.ebiom.2022.103993_bib0007
  article-title: The status of tuberculosis vaccine development
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(19)30625-5
– volume: 7
  start-page: 11290
  year: 2016
  ident: 10.1016/j.ebiom.2022.103993_bib0039
  article-title: T-cell activation is an immune correlate of risk in BCG vaccinated infants
  publication-title: Nat Commun
  doi: 10.1038/ncomms11290
– ident: 10.1016/j.ebiom.2022.103993_bib0048
– volume: 115
  start-page: 2472
  year: 2005
  ident: 10.1016/j.ebiom.2022.103993_bib0049
  article-title: Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin
  publication-title: J Clin Invest
  doi: 10.1172/JCI24617
– volume: 5
  year: 2017
  ident: 10.1016/j.ebiom.2022.103993_bib0016
  article-title: Pathology of tuberculosis: how the pathology of human tuberculosis informs and directs animal models
  publication-title: Microbiol Spectr
  doi: 10.1128/microbiolspec.TBTB2-0029-2016
– volume: 4
  start-page: e130090
  year: 2019
  ident: 10.1016/j.ebiom.2022.103993_bib0021
  article-title: Cytomegalovirus infection is a risk factor for tuberculosis disease in infants
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.130090
– volume: 381
  start-page: 2429
  year: 2019
  ident: 10.1016/j.ebiom.2022.103993_bib0044
  article-title: Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1909953
– volume: 39
  start-page: 7277
  year: 2021
  ident: 10.1016/j.ebiom.2022.103993_bib0011
  article-title: MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2021.06.049
– volume: 8
  start-page: e1132
  year: 2020
  ident: 10.1016/j.ebiom.2022.103993_bib0015
  article-title: Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study
  publication-title: Lancet Glob Health
  doi: 10.1016/S2214-109X(20)30288-6
– volume: 31
  start-page: e00021
  year: 2018
  ident: 10.1016/j.ebiom.2022.103993_bib0029
  article-title: Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection
  publication-title: Clin Microbiol Rev
  doi: 10.1128/CMR.00021-18
– volume: 18
  start-page: 1271
  year: 2019
  ident: 10.1016/j.ebiom.2022.103993_bib0056
  article-title: Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges
  publication-title: Expert Rev Vaccines
  doi: 10.1080/14760584.2019.1692657
– ident: 10.1016/j.ebiom.2022.103993_bib0061
– ident: 10.1016/j.ebiom.2022.103993_bib0054
– volume: 24
  start-page: 130
  year: 2018
  ident: 10.1016/j.ebiom.2022.103993_bib0055
  article-title: Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine
  publication-title: Nat Med
  doi: 10.1038/nm.4473
– volume: 590
  start-page: 630
  year: 2021
  ident: 10.1016/j.ebiom.2022.103993_bib0037
  article-title: Correlates of protection against SARS-CoV-2 in rhesus macaques
  publication-title: Nature
  doi: 10.1038/s41586-020-03041-6
– volume: 577
  start-page: 95
  year: 2020
  ident: 10.1016/j.ebiom.2022.103993_bib0059
  article-title: Prevention of tuberculosis in macaques after intravenous BCG immunization
  publication-title: Nature
  doi: 10.1038/s41586-019-1817-8
– ident: 10.1016/j.ebiom.2022.103993_bib0006
– volume: 4
  start-page: 2836
  year: 2013
  ident: 10.1016/j.ebiom.2022.103993_bib0033
  article-title: Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
  publication-title: Nat Commun
  doi: 10.1038/ncomms3836
– volume: 29
  start-page: 68
  year: 2021
  ident: 10.1016/j.ebiom.2022.103993_bib0017
  article-title: Ultra-low dose aerosol infection of mice with mycobacterium tuberculosis more closely models human tuberculosis
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2020.10.003
SSID ssj0001542358
Score 2.328731
SecondaryResourceType review_article
Snippet The Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new licensed...
SummaryThe Mycobacterium bovis BCG vaccine was first used in 1921, but has not controlled the global spread of tuberculosis (TB). There are still no new...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 103993
SubjectTerms Advanced Basic Science
Internal Medicine
Personal View
SARS-CoV-2
Tuberculosis
Vaccines
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9UwFA4yILgR315fRHBpsEmTplmJDg6DohtnYHYhrzpXLq3ctoo7_4P_0F_iSdJeblVmNm7TpGlOTnq-Q875DkLPwORZWzNPvOCOcGslMYFTUgvfqMIGbn1MTn7_oTo-5W_PxNleqa8YE5bpgbPgXnDwWbipnOIcXJmCGumtsIw1tmjqukxMoGDG9pypnB_MYw5oqiwnGClVxWfKoRTcFWJyO3iHjMWsc6XKhVlK7P0L6_Q3-vwziHLPKh3dQNcnOIlf5WXcRFdCewtdzQUmv99G705GG7Zu3HT9usdfjYvX6D1etxhwHw5bg7sGH8ZcPEIV_vXjJ_52bgYMfYdUpQqPPe47vOnaTy_voNOjNyeHx2Qqn0BcVbKBAJIoGpoI6AHnNMpZ8K2o9yKYolZMBs6M4oAgRMEC9VKEAG62KZ2QpirAc72LDtquDfcRpk5CO3ecggMDGNJSbqlnVdO4ooZtWCE2S0-7iVs8lrjY6DmI7LNOItdR5DqLfIWe7wZ9ydQaF3d_Hbdl1zXyYqcG0BY9aYu-TFtWiM-bqufUU_hZwovWF88t_zUs9NOB7zXVPdOF_hjVLWobi7FqUsLIajdywjQZq1w-5dNZ5zSc-HiNY9rQjb1mVbrb5Iqu0L2sgzuhlCKWThEMPnihnQupLZ-06_PEKq5SnrR48D_E_BBdi0vJgaGP0MGwHcNjAG-DfZLO6W-CUzyk
  priority: 102
  providerName: Directory of Open Access Journals
Title Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?
URI https://www.clinicalkey.com/#!/content/1-s2.0-S2352396422001773
https://www.clinicalkey.es/playcontent/1-s2.0-S2352396422001773
https://dx.doi.org/10.1016/j.ebiom.2022.103993
https://www.ncbi.nlm.nih.gov/pubmed/35427852
https://www.proquest.com/docview/2651690491
https://pubmed.ncbi.nlm.nih.gov/PMC9002045
https://doaj.org/article/41064a6c94454901a7db5b22fb0f8834
Volume 79
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2352-3964
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001542358
  issn: 2352-3964
  databaseCode: KQ8
  dateStart: 20141101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2352-3964
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001542358
  issn: 2352-3964
  databaseCode: KQ8
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2352-3964
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001542358
  issn: 2352-3964
  databaseCode: DOA
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 2352-3964
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001542358
  issn: 2352-3964
  databaseCode: AKRWK
  dateStart: 20141101
  isFulltext: true
  providerName: Library Specific Holdings
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2352-3964
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0001542358
  issn: 2352-3964
  databaseCode: RPM
  dateStart: 20140101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2352-3964
  dateEnd: 20250930
  omitProxy: true
  ssIdentifier: ssj0001542358
  issn: 2352-3964
  databaseCode: M48
  dateStart: 20141101
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELZKEaiXijfLozISR4xix87jUFVQURVQkRBdqTfLdpx20SqhcVLaf9-xkywElnLZQ9YTW5Nx5vvieSD0Glye1hkrSCG4IVzrlCjLKclEUeaRtlwXPjn56EtyOOefTsTJBhq7og4KdGupne8nNW-Wby_Pr_Zgw-_-itWyPlcdyB5jPokc5r-FboNrYt7Mjwa836cNc58aOlYfWi-7he7GwnegEGzirEJN_4nP-huT_hla-ZuvOriHtgeQid_1VnEfbdjqAbrTt528eog-HnfaNqZb1m7h8IUy_nDd4UWFAQ1i2yhcl3jfZ-gRmmOCf56pFsPINnSuwp3DrsbLujrde4TmBx-O9w_J0FKBmCRmLQF0EZU0FKUH7FPmRgPfokUhrIqynKWWM5VzQBUiYpYWqbAWqLeKjUhVEgGbfYw2q7qyTxGmJoXr3HAKpAZwpaZc04IlZWmirMyyGWKj7qQZ6o37thdLOQaWfZdB99LrXva6n6E3K6EffbmNm4e_9w9lNdTXyg4X6uZUDltPcmC9XCUm5xzIcERVWmihGSt1BMuM-Qzx8ZHKMR0VXqBwo8XNc6frxKwbbVhS6ZiM5DcwORbnQPR8_FqagmSykhxwTo9f_j_lq9HiJLwF_NGOqmzdOcmScN7JczpDT3oLXCllNGZY8MQ2J1qb_lMtzkKl8TzkTotn_7znc7Tl19dHgL5Am23T2ZeA0lq9E75uwO_nr9lO2IXXbtk3tQ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tuberculosis+vaccines+in+the+era+of+Covid-19+-+what+is+taking+us+so+long%3F&rft.jtitle=EBioMedicine&rft.au=Dockrell%2C+Hazel+M&rft.au=McShane%2C+Helen&rft.date=2022-05-01&rft.eissn=2352-3964&rft.volume=79&rft.spage=103993&rft_id=info:doi/10.1016%2Fj.ebiom.2022.103993&rft_id=info%3Apmid%2F35427852&rft.externalDocID=35427852
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F23523964%2Fcov200h.gif